OTLK Outlook Therapeutics

Outlook Therapeutics to Present at Two Upcoming Investor Conferences

Outlook Therapeutics to Present at Two Upcoming Investor Conferences

MONMOUTH JUNCTION, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that of Outlook Therapeutics, will present at two upcoming investor conferences in September.

The following are the details for the conferences.

  • Event: Fireside Chat Discussion and Q&A
  • Date and Time: Monday, September 14, 2020 at 4:30 PM EDT

  • Event: Fireside Chat Discussion and Q&A
  • Date and Time: Monday, September 21, 2020 at 2:30 PM EDT

In addition to the presentations, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend either of the conferences.

A live video webcast of the presentations will be accessible on the page of the section of the Outlook Therapeutics website, , approximately two hours after each event and will be archived for 90 days following the event.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway. For more information, please visit .



CONTACTS:



Media Inquiries:

Jessica Morris

Account Executive

LaVoie Health Science

T: 857.701.9731

Investor Inquiries:       

Jenene Thomas

Chief Executive Officer

JTC Team, LLC

T: 833.475.8247 



EN
08/09/2020

Underlying

OTLKOutlook Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Outlook Therapeutics

 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This com...

5h / 12m 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healt...

Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference Live webcast fireside chat on Tuesday, December 2nd at 10:00 AM ET ISELIN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that Bob Jahr, Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 10:00 AM ET. In addition to the fireside chat,...

November 24, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Announces Acceptance of Biologics License Applica...

Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD Prescription Drug User Fee Act (PDUFA) goal date of December 31, 2025 ISELIN, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational oph...

November 13, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Re-Submits Biologics License Application for ONS-...

Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 ISELIN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has re-submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010, after receiving the official minutes from the FDA Type A meeting conducted in September 2025. ONS-5010 is an investigational ophthalmic formulation of bevacizumab which, if approved, will be br...

November 3, 2025 1 EN
 PRESS RELEASE
Free
OTLK Outlook Therape...

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Outlook Therapeutics Provides Update on Type A Meeting with FDA ISELIN, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) --   (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has completed the Type A Meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) dated August 27, 2025 regarding the biologics license application (BLA) resubmission for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet ...

September 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch